These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34407844)

  • 1. Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer.
    Tsimberidou AM; Shaw JV; Juric D; Verschraegen C; Weise AM; Sarantopoulos J; Lopes G; Nemunaitis J; Mita M; Park H; Ellers-Lenz B; Tian H; Xiong W; Kaleta R; Kurzrock R
    J Hematol Oncol; 2021 Aug; 14(1):127. PubMed ID: 34407844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study.
    Angevin E; Cassier PA; Italiano A; Gonçalves A; Gazzah A; Terret C; Toulmonde M; Gravis G; Varga A; Parlavecchio C; Paci A; Poinsignon V; Soria JC; Drubay D; Hollebecque A
    Eur J Cancer; 2017 Sep; 83():194-202. PubMed ID: 28750271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers.
    DeSelm L; Huck B; Lan R; Neagu C; Potnick J; Xiao Y; Chen X; Jones R; Richardson TE; Heasley BH; Haxell T; Moore J; Tian H; Georgi K; Rohdich F; Sutton A; Johnson T; Mochalkin I; Jackson J; Lin J; Crowley L; Machl A; Clark A; Wilker E; Sherer B; Goutopoulos A
    J Med Chem; 2021 Oct; 64(19):14603-14619. PubMed ID: 34596404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier.
    Machl A; Wilker EW; Tian H; Liu X; Schroeder P; Clark A; Huck BR
    Am J Cancer Res; 2016; 6(4):806-18. PubMed ID: 27186432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer.
    Azaro A; Rodon J; Calles A; Braña I; Hidalgo M; Lopez-Casas PP; Munoz M; Westwood P; Miller J; Moser BA; Ohnmacht U; Bumgardner W; Benhadji KA; Calvo E
    Invest New Drugs; 2015 Jun; 33(3):710-9. PubMed ID: 25902900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab.
    Fukuoka S; Koga Y; Yamauchi M; Koganemaru S; Yasunaga M; Shitara K; Doi T; Yoshino T; Kuronita T; Elenbaas B; Wahra P; Zhang H; Crowley L; Jenkins MH; Clark A; Kojima T
    Sci Rep; 2023 Sep; 13(1):16017. PubMed ID: 37749105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast Cancer Prevention.
    Wang X; Yao J; Wang J; Zhang Q; Brady SW; Arun B; Seewaldt VL; Yu D
    Cancer Prev Res (Phila); 2017 Nov; 10(11):641-650. PubMed ID: 28877935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors.
    Hong DS; Henary H; Falchook GS; Naing A; Fu S; Moulder S; Wheler JJ; Tsimberidou A; Durand JB; Khan R; Yang P; Johansen M; Newman RA; Kurzrock R
    Invest New Drugs; 2014 Dec; 32(6):1204-12. PubMed ID: 24919855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients.
    Vicier C; Sfumato P; Isambert N; Dalenc F; Robert M; Levy C; Rezai K; Provansal M; Adélaïde J; Garnier S; Guille A; Carbuccia N; Popovici C; Charafe-Jauffret E; Chaffanet M; Birnbaum D; Pakradouni J; Bertucci F; Boher JM; Sabatier R; Gonçalves A
    Eur J Cancer; 2021 Dec; 159():205-214. PubMed ID: 34781168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment.
    Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
    Breast Cancer Res; 2014 Jan; 16(1):R6. PubMed ID: 24447434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours.
    Tolcher A; Goldman J; Patnaik A; Papadopoulos KP; Westwood P; Kelly CS; Bumgardner W; Sams L; Geeganage S; Wang T; Capen AR; Huang J; Joseph S; Miller J; Benhadji KA; Brail LH; Rosen LS
    Eur J Cancer; 2014 Mar; 50(5):867-75. PubMed ID: 24440085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
    Ganesan P; Janku F; Naing A; Hong DS; Tsimberidou AM; Falchook GS; Wheler JJ; Piha-Paul SA; Fu S; Stepanek VM; Lee JJ; Luthra R; Overman MJ; Kopetz ES; Wolff RA; Kurzrock R
    Mol Cancer Ther; 2013 Dec; 12(12):2857-63. PubMed ID: 24092809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia.
    Lang F; Wunderle L; Badura S; Schleyer E; Brüggemann M; Serve H; Schnittger S; Gökbuget N; Pfeifer H; Wagner S; Ashelford K; Bug G; Ottmann OG
    BMC Pharmacol Toxicol; 2020 Sep; 21(1):70. PubMed ID: 32993794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
    Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F
    Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
    Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
    Guerin M; Rezai K; Isambert N; Campone M; Autret A; Pakradouni J; Provansal M; Camerlo J; Sabatier R; Bertucci F; Charafe-Jauffret E; Hervieu A; Extra JM; Viens P; Lokiec F; Boher JM; Gonçalves A
    Eur J Cancer; 2017 Nov; 86():28-36. PubMed ID: 28950146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors.
    Hudis C; Swanton C; Janjigian YY; Lee R; Sutherland S; Lehman R; Chandarlapaty S; Hamilton N; Gajria D; Knowles J; Shah J; Shannon K; Tetteh E; Sullivan DM; Moreno C; Yan L; Han HS
    Breast Cancer Res; 2013 Nov; 15(6):R110. PubMed ID: 24252402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.
    Esteva FJ; Guo H; Zhang S; Santa-Maria C; Stone S; Lanchbury JS; Sahin AA; Hortobagyi GN; Yu D
    Am J Pathol; 2010 Oct; 177(4):1647-56. PubMed ID: 20813970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.
    Bendell JC; Varghese AM; Hyman DM; Bauer TM; Pant S; Callies S; Lin J; Martinez R; Wickremsinhe E; Fink A; Wacheck V; Moore KN
    Clin Cancer Res; 2018 Jul; 24(14):3253-3262. PubMed ID: 29636360
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.